DoseGear research brief
Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.
DG Peptide Protocols
Extensively StudiedHealing & RecoveryCognitive
Ara 290
Cibinetide
Tissue-Protective Peptide | Innate Repair Receptor Agonist
Research overview
Mechanism of action
Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Engineered EPO-derived helix-B-surface peptide, also called cibinetide.
What it is researched for
Small-fiber neuropathy, tissue protection, and diabetic-complication research through proposed innate-repair-receptor signaling.
Research observation window
Human neuropathy studies used 28 days; a diabetic macular-edema pilot used 12 weeks. Some metabolic observations persisted four weeks after treatment.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Neuropathy Treatment | 4 mg daily | Once daily | SubQ |
| Tissue Protection | 1-8 mg daily | Once daily | SubQ |
| Acute Intervention | 2 mg | 3x weekly | IV |
Reference cycle
28 days
Reference storage
Lyophilized: 2-8°C refrigerated, protect from light; Reconstituted: use immediately or refrigerate up to 24 hours
Safety context
Reported side effects
- Excellent safety profile in clinical trials with no serious drug-related adverse events
Contraindications & cautions
- Recent anti-TNF therapy (within 6 months)
- EPO use (within 2 months)
- Pregnancy
- BMI > 34 kg/m²
Scientific references
- 01
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Scientific citationCibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science (2017). - 02
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
Scientific citationARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine (2015). - 03
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
Scientific citationA Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Translational Vision Science & Technology (2020). - 04
A Small Nonerythropoietic Helix B Surface Peptide Based Upon Erythropoietin Structure Is Cardioprotective Against Ischemic Myocardial Damage
Scientific citationA Small Nonerythropoietic Helix B Surface Peptide Based Upon Erythropoietin Structure Is Cardioprotective Against Ischemic Myocardial Damage. Proceedings of the National Academy of Sciences (2008).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.